Why CRISPR Therapeutics AG Jumped 11.7% in June – Motley Fool
Motley Fool |
Why CRISPR Therapeutics AG Jumped 11.7% in June
Motley Fool First, CRISPR and MaSTherCell SA announced that they have signed a development and manufacturing agreement related to allogeneic CAR-T therapies. The deal calls for MaSTherCell to handle the development and manufacturing of CRISPR's compound … |
